Correction to: Lipegfilgrastim for the prophylaxis and treatment of chemotherapy-induced neutropenia
Ratti M, Tomasello G. Lipegfilgrastim for the prophylaxis and treatment of chemotherapy-induced neutropenia. Expert Rev Clin Pharm 2015:8(1):15-24.
Following publication of this article the below errors have been identified:
1. In the G-CSFs subsection and elsewhere in the manuscript the authors state the following
Lipegfilgrastim, an alternative glycol-pegylated G-CSF, is approved as a biosimilar for pegfilgrastim in the UK and by the EMA and it is marketed as Lonquex®
However, Lonquex is a glycoPEGylated, long-acting form of recombinant human filgrastim, classified with a distinct ATC* code – therefore it is not a biosimilar of pegfilgrastim.
2. The manuscript states that pegfilgrastim has a recommended dose of 100 µg/kg in children, however there is no official indication for the drug in children and this comment should be disregarded.
3. In the ‘Lipegfilgrastim: chemical structure and rationale for its development’ subsection the authors state the following
lipegfilgrastim shows a longer half-life compared with pegfilgrastim in vitro
This should read
lipegfilgrastim shows a longer half-life compared with pegfilgrastim in vivo
4. In the ‘Efficacy of lipegfilgrastim in preventing CIN & FN: results of Phase Ill trials’ subsection. The manuscript reads
No patient in the lipegfilgrastim arm (0/53) and 13.3% patients in the placebo cohort (4/30) presented FN during cycle 1 (p = 0.064)
The p value here is incorrect and should be 0.0064. It should also be noted that this relates to the elderly.